Table 2.
Summary of all ongoing active trials investigating panobinostat in patients with MM.
| A/a | NCT number (study name) | Phase | Comparing arms | Intervention/treatment | Patients characteristics |
|---|---|---|---|---|---|
| 1 | NCT01496118 | I/II | Experimental: carfilzomib and panobinostat | Carfilzomib and panobinostat | Relapse/refractory after at least one previous bortezomib-containing regimen |
|
| |||||
| 2 | NCT01965353 | I | Experimental: panobinostat, dexamethasone, lenalidomide, and bortezomib | Dexamethasone and lenalidomide and bortezomib and panobinostat | Relapse/refractory after at least two lines of treatment |
|
| |||||
| 3 | NCT02722941 | II | Panobinostat: 20 mg by mouth three [3] times per week, every other week, of a 28-day schedule Panobinostat: 10 mg by mouth daily for seven [7] days, every other week, of a 28-day schedule |
Panobinostat as maintenance therapy after HDT + ASCT | Patients must have achieved at least PR after ASCT |
|
| |||||
| 4 | NCT03256045 | II | Experimental: carfilzomib and panobinostat | Carfilzomib and panobinostat | Relapse/refractory after at least one previous line of treatment |
|
| |||||
| 5 | NCT01301807 | I | Experimental: carfilzomib and panobinostat | Carfilzomib and panobinostat | Relapsed/refractory MM with failure to at least two lines of MM treatment including at least one IMiD (thalidomide, lenalidomide) and proteasome inhibitor (bortezomib) |
|
| |||||
| 6 | NCT02057640 | I/II | Experimental: ixazomib, panobinostat, and dexamethasone | Ixazomib and panobinostat and dexamethasone | Relapsed/refractory MM after receiving at least one IMiD (thalidomide, lenalidomide) and proteasome inhibitor (bortezomib) |
|
| |||||
| 7 | NCT00918333 | I/II | Experimental: everolimus and panobinostat | Everolimus and panobinostat | Relapsed/refractory myeloma requiring therapy, who have failed, are unable to tolerate, or refused other available active therapies |
|
| |||||
| 8 | NCT02506959 | II | Experimental: panobinostat, gemcitabine hydrochloride, busulfan, and melphalan ASCT | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and melphalan ASCT | Refractory/relapsed myeloma |
|
| |||||
| 9 | NCT02654990 | II | Experimental: panobinostat, bortezomib, and dexamethasone Investigate 3 different panobinostat regimens |
Panobinostat and bortezomib and dexamethasone | Refractory/relapsed myeloma with 1 to 4 prior lines of treatment |